Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

Core Insights - Omnicell, Inc. reported a significant increase in adjusted earnings per share (EPS) for Q4 2024, reaching 60 cents, an 81.8% year-over-year surge, surpassing the Zacks Consensus Estimate by 5.2% [1][2] - Total revenues for Q4 2024 were $306.9 million, reflecting an 18.6$1.105 billion and $1.155 billion, with adjusted EPS expected in the range of$1.65 to $1.85 [7] Financial Performance - The GAAP EPS for Q4 2024 was 34 cents, compared to a loss of 32 cents in the same period last year [2] - For the full year, adjusted earnings were$1.71 per share, down 10.4% from the previous year [2] - Gross profit for Q4 increased by 34.5% year-over-year to $141.8 million, with a gross margin expansion of 547 basis points to 46.2$182.3 million, while service and other revenues increased by 10.1% to $124.6 million [4] - Total revenues for the full year 2024 were reported at$1.11 billion, down 3% from the previous year [3] Cash Flow and Financial Position - At the end of Q4 2024, Omnicell had cash and cash equivalents of $369.2 million, down from$468 million at the end of Q4 2023 [6] - Cumulative cash flow from operating activities at the end of Q4 was $187.7 million, compared to$181.1 million in the prior year [6] Strategic Developments - The company achieved notable wins in Q4, including service renewals and expansions with major medical centers and new contracts for specialty pharmacy programs [10] - The XT Amplify innovation program continues to gain traction, contributing to the company's growth [10] Market Reaction - Following the earnings announcement on February 6, OMCL shares rose by 1.9%, closing at $40.16 [3]